Interestingly, increased survival associated with low ATG12-expression was observed in ovarian cancer (Figure 3A, P = 0.034; HR:1.32 (1.022–1.716)), infiltrating ductal breast cancer (Figure 3B, P = 0.029; HR 1.457 (1.040–2.041)), ductal pancreatic cancer (Figure 3C, P = 0.041; HR:1.575 (1.019–2.433)), renal clear cell carcinoma (Figure 3D, P = 0.017; HR:1.409 (1.064–1.865)), renal papillary cell carcinoma (Figure 3E, P = 0.030; HR 1.933 (1.067–3.491)) and kidney chromophobe cancer (Figure 3F, P = 0.042; HR:4.334 (1.052–17.85)). This evidence concerns the gene ATG12 and clear cell renal carcinoma.